Immune Response to initiate clinical study in HIV patients

Published: 18-Jun-2004

IR103, The Immune Response Corporation newest product candidate in the development for the treatment of HIV will enter Phase I clinical trials.


IR103, The Immune Response Corporation newest product candidate in the development for the treatment of HIV will enter Phase I clinical trials.

This trial will represent the first human experience with the Company's new HIV product candidate, which combines its patented HIV-1 Immunogen with Amplivax, an immunostimulatory oligonucleotide adjuvant.

'The commencement of this trial represents a major milestone in the company's development plan for its HIV products. The recent laboratory data we presented on IR103 has encouraged us to pursue clinical trials with this product candidate as quickly as possible,' said Dr John Bonfiglio, chief executive officer of The Immune Response Corporation. 'Clearance of our trial in Canada is an important first step in evaluating IR103 in humans. In addition to this trial in patients currently on antiretroviral therapy, we will be studying IR103 in drug naive patients later this year.'

You may also like